Pharmaceuticals News and Research

RSS

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.

26 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

Queen's University leads world's first trial of new combination treatment for advanced prostate cancer

Queen's University Belfast, in partnership with the Belfast Trust, is leading the world's first ever trial of a new combination of cancer therapies for patients with advanced prostate cancer, with the hope of prolonging their lives.

26 Feb 2016

Japanese bioengineers tweak E. coli genes to pump out morphine precursor

A common gut microbe could soon be offering us pain relief. Japanese bioengineers have tweaked Escherichia coli genes so that they pump out thebaine, a morphine precursor that can be modified to make painkillers. The genetically modified E. coli produces 300 times more thebaine with minimal risk of unregulated use compared to a recently developed method involving yeast.

26 Feb 2016

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan plc, a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration to market ACZONE (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older.

26 Feb 2016

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2015.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).

25 Feb 2016

Zika outbreak highlights need for developing and evaluating new vaccines for pregnant women

The recent outbreak of Zika virus disease and its link to fetal development highlights the need for pregnant women and those of reproductive age to be a priority group for developing and evaluating new vaccines and vaccine guidelines for Zika and other emerging infectious diseases, say the authors of a new Viewpoint article in JAMA.

25 Feb 2016

Tackling Zika virus: Challenges ahead

Health officials, drug companies, governments and the public are scrambling to understand and combat the Zika virus. The virus was first identified almost 70 years ago, but little is known about it. And now, officials suspect it could be related to a rise in microcephaly cases in affected countries.

25 Feb 2016

Vertical Pharmaceuticals launches breakthrough prenatal vitamin supplement: OB Complete Gold

OB Complete Gold is a breakthrough innovation in prenatal vitamin supplements that contains the advanced technology OmEGGa DHA, providing a novel egg-based DHA that comes from cage-free hens.

25 Feb 2016

New approach to prevent mother to child transmission of HIV

The first findings from a study in the Kingdom of Swaziland on a new approach to reduce mother to child transmission of HIV were presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

24 Feb 2016

PolyPid closes $22 million private equity financing

PolyPid Ltd., an emerging clinical-stage specialty pharmaceutical company, focused primarily on the development of post-surgical anti-infection pipeline, announced today that it closed a $22 million private equity financing.

24 Feb 2016

New clinical trial launched to test potential drug that could help immune system combat cancer

Cancer Research UK's Centre for Drug Development, in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours.

24 Feb 2016

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona (IBB-UAB), in collaboration with the biopharmaceutical company SOM Biotech, located in the Barcelona Science Park (PCB), have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug, SOM0226 (tolcapone) that could significantly improve the pharmacological treatment of familial transthyretin amyloidosis (ATTR).

24 Feb 2016

Diversigen, Baylor Miraca to provide customers access to targeted genomics and metabolomics services

Diversigen, Inc., the leading provider of comprehensive microbiome analysis services, today announced a strategic partnership with Baylor Miraca Genetics Laboratories, a global leader in genetic testing, to provide their customers access to a broad range of targeted genomics and metabolomics services.

23 Feb 2016

Dapivirine ring can help prevent HIV-1 infection in women

In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women.

23 Feb 2016

MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

The Mount Desert Island Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, resulting from chemotherapy treatment for ovarian, breast, lung, pancreas and other cancers. The drugs also have potential applications for the treatment of peripheral nerve damage caused by diabetes, traumatic injuries and other conditions.

23 Feb 2016

Study identifies new mechanism for controlling HIV replication

Researchers at University of California, San Diego School of Medicine have discovered that HIV infection of human immune cells triggers a massive increase in methylation, a chemical modification, to both human and viral RNA, aiding replication of the virus.

23 Feb 2016

Pharmaceuticals News and Research

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Queen's University leads world's first trial of new combination treatment for advanced prostate cancer

Japanese bioengineers tweak E. coli genes to pump out morphine precursor

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Zika outbreak highlights need for developing and evaluating new vaccines for pregnant women

Tackling Zika virus: Challenges ahead

Vertical Pharmaceuticals launches breakthrough prenatal vitamin supplement: OB Complete Gold

New approach to prevent mother to child transmission of HIV

PolyPid closes $22 million private equity financing

New clinical trial launched to test potential drug that could help immune system combat cancer

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Diversigen, Baylor Miraca to provide customers access to targeted genomics and metabolomics services

Dapivirine ring can help prevent HIV-1 infection in women

MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

Study identifies new mechanism for controlling HIV replication

Event guide: World ADC San Diego eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring